vs
HERC HOLDINGS INC（HRI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
HERC HOLDINGS INC的季度营收约是Revvity的1.5倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs -2.1%，领先14.8%），HERC HOLDINGS INC同比增速更快（32.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $94.0M），过去两年HERC HOLDINGS INC的营收复合增速更高（1343.1% vs 9.0%）
Herc Holdings Inc.是北美领先的设备租赁服务供应商，主营工程重型机械、电动工具、临时供电及温控系统租赁业务，服务覆盖建筑、工业、商业活动、基建及政府等领域，业务遍布美国与加拿大。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HRI vs RVTY — 直观对比
营收规模更大
HRI
是对方的1.5倍
$772.1M
营收增速更快
HRI
高出26.4%
5.9%
净利率更高
RVTY
高出14.8%
-2.1%
自由现金流更多
RVTY
多$67.8M
$94.0M
两年增速更快
HRI
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $-24.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -2.1% | 12.7% |
| 营收同比 | 32.3% | 5.9% |
| 净利润同比 | -33.3% | 3.9% |
| 每股收益（稀释后） | $-0.72 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRIRVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $30.1M | $772.1M | ||
| Q3 25 | $10.1M | $698.9M | ||
| Q2 25 | $6.3M | $720.3M | ||
| Q1 25 | $4.2M | $664.8M | ||
| Q4 24 | $4.1M | $729.4M | ||
| Q3 24 | — | $684.0M | ||
| Q2 24 | — | $691.7M |
净利润HRIRVTY
| Q1 26 | $-24.0M | — | ||
| Q4 25 | $-99.9M | $98.4M | ||
| Q3 25 | $-7.5M | $46.7M | ||
| Q2 25 | $-10.8M | $53.9M | ||
| Q1 25 | $-14.1M | $42.2M | ||
| Q4 24 | $-10.3M | $94.6M | ||
| Q3 24 | — | $94.4M | ||
| Q2 24 | — | $55.4M |
毛利率HRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 42.3% | — | ||
| Q3 25 | 25.8% | 53.6% | ||
| Q2 25 | 53.1% | 54.5% | ||
| Q1 25 | 35.0% | 56.5% | ||
| Q4 24 | 21.4% | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率HRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | -77.4% | 14.5% | ||
| Q3 25 | -153.5% | 11.7% | ||
| Q2 25 | -147.4% | 12.6% | ||
| Q1 25 | -242.7% | 10.9% | ||
| Q4 24 | -206.3% | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% |
净利率HRIRVTY
| Q1 26 | -2.1% | — | ||
| Q4 25 | -331.7% | 12.7% | ||
| Q3 25 | -74.1% | 6.7% | ||
| Q2 25 | -171.4% | 7.5% | ||
| Q1 25 | -332.8% | 6.4% | ||
| Q4 24 | -250.3% | 13.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 8.0% |
每股收益（稀释后）HRIRVTY
| Q1 26 | $-0.72 | — | ||
| Q4 25 | $-0.36 | $0.86 | ||
| Q3 25 | $-0.03 | $0.40 | ||
| Q2 25 | $-0.08 | $0.46 | ||
| Q1 25 | $-0.15 | $0.35 | ||
| Q4 24 | $-0.15 | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $43.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $7.3B |
| 总资产 | $13.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HRIRVTY
| Q1 26 | $43.0M | — | ||
| Q4 25 | $550.7M | $919.9M | ||
| Q3 25 | $432.8M | $931.4M | ||
| Q2 25 | $67.6M | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $30.0M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务HRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $300.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益HRIRVTY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $437.8M | $7.3B | ||
| Q3 25 | $486.1M | $7.4B | ||
| Q2 25 | $90.8M | $7.6B | ||
| Q1 25 | $26.1M | $7.6B | ||
| Q4 24 | $16.6M | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B |
总资产HRIRVTY
| Q1 26 | $13.6B | — | ||
| Q4 25 | $1.1B | $12.2B | ||
| Q3 25 | $550.2M | $12.1B | ||
| Q2 25 | $152.0M | $12.4B | ||
| Q1 25 | $104.6M | $12.4B | ||
| Q4 24 | $109.6M | $12.4B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $13.4B |
负债/权益比HRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $277.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $94.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.3% | 21.0% |
| 资本支出强度资本支出/营收 | 13.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $60.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HRIRVTY
| Q1 26 | $277.0M | — | ||
| Q4 25 | $-12.7M | $182.0M | ||
| Q3 25 | $-11.0M | $138.5M | ||
| Q2 25 | $-8.4M | $134.3M | ||
| Q1 25 | $-6.7M | $128.2M | ||
| Q4 24 | $-8.1M | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $158.6M |
自由现金流HRIRVTY
| Q1 26 | $94.0M | — | ||
| Q4 25 | $-14.3M | $161.8M | ||
| Q3 25 | $-11.1M | $120.0M | ||
| Q2 25 | $-8.5M | $115.5M | ||
| Q1 25 | $-6.8M | $112.2M | ||
| Q4 24 | $-8.1M | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率HRIRVTY
| Q1 26 | 8.3% | — | ||
| Q4 25 | -47.6% | 21.0% | ||
| Q3 25 | -110.2% | 17.2% | ||
| Q2 25 | -135.5% | 16.0% | ||
| Q1 25 | -160.8% | 16.9% | ||
| Q4 24 | -197.1% | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度HRIRVTY
| Q1 26 | 13.6% | — | ||
| Q4 25 | 5.3% | 2.6% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 0.7% | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率HRIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRI
| Equipment rental | $981.0M | 86% |
| Sales of rental equipment | $138.0M | 12% |
| Sales of new equipment, parts and supplies | $13.0M | 1% |
| Service and other revenue | $7.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
